高级检索
    周德, 主鸿鹄, 陈晓梅. Venetoclax联合小剂量阿糖胞苷治疗不耐受强化疗的初诊急性髓系白血病[J]. 循证医学, 2022, 22(2): 91-94. DOI: 10.12019/j.issn.1671-5144.2022.02.005
    引用本文: 周德, 主鸿鹄, 陈晓梅. Venetoclax联合小剂量阿糖胞苷治疗不耐受强化疗的初诊急性髓系白血病[J]. 循证医学, 2022, 22(2): 91-94. DOI: 10.12019/j.issn.1671-5144.2022.02.005
    shu
    ZHOU De, ZHU Hong-hu, CHEN Xiao-mei. Venetoclax Plus Low-Dose Cytarabine for Newly Diagnosed Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy[J]. Journal of Evidence-Based Medicine, 2022, 22(2): 91-94. DOI: 10.12019/j.issn.1671-5144.2022.02.005
    Citation: ZHOU De, ZHU Hong-hu, CHEN Xiao-mei. Venetoclax Plus Low-Dose Cytarabine for Newly Diagnosed Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy[J]. Journal of Evidence-Based Medicine, 2022, 22(2): 91-94. DOI: 10.12019/j.issn.1671-5144.2022.02.005
    shu

    Venetoclax联合小剂量阿糖胞苷治疗不耐受强化疗的初诊急性髓系白血病

    Venetoclax Plus Low-Dose Cytarabine for Newly Diagnosed Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

      摘要
      • HTML全文
      • 参考文献(8)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回